Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors-Reference-Cited by-同舟云学术

Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors

Published:2017-07-10 Issue:10 Volume:18 Page:
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Duan Ping¹,Fan Lili²,Gao Quansheng³,Silwal Bal Mukunda²,Ren Mulan²,Shen Yang²,Qu Wanglei¹

Affiliation:

1. Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China

2. Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing 210009, China

3. Laboratory of the Animal Center, Academy of Military Medical Sciences, Haidian District, Beijing 100850, China

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition;Open Life Sciences;2022-01-01

2. Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics;Therapeutic Advances in Medical Oncology;2022-01

3. miR‑152‑mediated MKK7 downregulation is attenuated by MYCNOS in ovarian adenocarcinoma;Oncology Letters;2021-10-20

4. Theasaponin E1 Inhibits Platinum-Resistant Ovarian Cancer Cells through Activating Apoptosis and Suppressing Angiogenesis;Molecules;2021-03-17

5. Blood bioactive sphingolipids in patients with advanced serous epithelial ovarian cancer – mass spectrometry analysis;Archives of Medical Science;2021-01-05